PBOV1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells

Wang,Lan; Niu,Chun-Hao; Wu,Shu; Wu,Hong-Mei; Ouyang,Fei; He,Mian; He,Shan-Yang

doi:10.3892/or.2015.4396

PBOV1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells

Authors:
- Lan Wang
- Chun-Hao Niu
- Shu Wu
- Hong-Mei Wu
- Fei Ouyang
- Mian He
- Shan-Yang He
View Affiliations

Affiliations: Department of Pathogen Biology and Immunology, School of Basic Courses, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, P.R. China, Department of Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P.R. China, Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510700, P.R. China
Published online on: November 4, 2015 https://doi.org/10.3892/or.2015.4396
Pages: 488-496

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate and breast cancer overexpressed 1 (PBOV1) is significantly upregulated in prostate, breast and bladder cancer, while its expression status in ovarian cancer and its clinical significance are unclear. We examined the expression levels of PBOV1 mRNA and protein in ovarian cancer cell lines and primary tissues using real-time PCR and western blotting. Immunohistochemistry was employed to analyze PBOV1 expression in 17 normal ovaries, 13 cystadenoma tissues, 14 borderline tumor tissues, and 165 clinicopathologically characterized ovarian cancers. There was negative PBOV1 expression in the 17 normal ovarian epithelial tissues. Compared to the normal ovarian epithelial cells, PBOV1 mRNA and protein were overexpressed in ovarian cancer cell lines. There was high PBOV1 protein expression in the ovarian cancer tissues from 59 of the 165 (35.8%) patients; PBOV1 expression was weak in 106 (64.2%) patients. Notably, there were significant negative associations between high PBOV1 expression and ascending histological grade, late pT/pN/pM, and International Federation of Gynecology and Obstetrics (FIGO) stage (P<0.05). Patients with high PBOV1 expression had longer overall survival; patients with low PBOV1 expression had shorter survival. Multivariate analysis revealed that PBOV1 upregulation is an independent prognostic indicator for ovarian cancer and might serve as a tumor-suppressor gene. Furthermore, PBOV1 overexpression inhibited ovarian cancer cell proliferation and tumorigenesis in vitro and in a tumor transplantation nude mouse model. In conclusion, our results suggest that PBOV1 may play an important role in suppressing ovarian cancer proliferation and carcinogenesis. PBOV1 may be a novel and useful prognostic marker and potential target for treating human ovarian cancer.

View Figures

View References

1	Whitmore SE, Rosenshein NB and Provost TT: Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore). 73:153–160. 1994. View Article : Google Scholar
2	Markman M, Webster K, Zanotti K, Peterson G, Kulp B and Belinson J: Survival following the documentation of platinum and taxane resistance in ovarian cancer: A single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol. 93:699–701. 2004. View Article : Google Scholar : PubMed/NCBI
3	No authors listed. Debulking surgery in ovarian cancer. J Clin Oncol. 4:1716–1717. 1986.PubMed/NCBI
4	Rossing MA, Wicklund KG, Cushing-Haugen KL and Weiss NS: Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 102:222–229. 2010. View Article : Google Scholar : PubMed/NCBI
5	Chudecka-Głaz AM, Cymbaluk-Płoska AA, Menkiszak JL, Sompolska-Rzechuła AM, Tołoczko-Grabarek AI and Rzepka-Górska IA: Serum He4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 7:622014. View Article : Google Scholar
6	DiSaia PJ and Bloss JD: Treatment of ovarian cancer: New strategies. Gynecol Oncol. 90:S24–S32. 2003. View Article : Google Scholar : PubMed/NCBI
7	Mantha S, Sarasohn D, Ma W, Devlin SM, Chi DS, Roche KL, Suidan RS, Woo K and Soff GA: Ovarian vein thrombosis after debulking surgery for ovarian cancer: Epidemiology and clinical significance. Am J Obstet Gynecol. 213:208.e1–e4. 2015. View Article : Google Scholar
8	Krukovskaia LL, Samusik ND, Shilov ES, Polev DE and Kozlov AP: Tumor-specific expression of PBOV1, a new gene in evolution. Vopr Onkol. 56:327–332. 2010.In Russian.
9	Kamagata C, Tsuji N, Kondoh K, Sasaki M, Kobayashi D, Yagihashi A and Watanabe N: Enhanced expression of the uROC28 gene in human breast cancer: Relationship to ERBB2 gene expression. Anticancer Res. 22:4087–4091. 2002.
10	Doak SH, Jenkins SA, Hurle RA, Varma M, Hawizy A, Kynaston HG and Parry JM: Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Cancer Genet Cytogenet. 176:161–165. 2007. View Article : Google Scholar : PubMed/NCBI
11	Loizidou MA, Cariolou MA, Neuhausen SL, Newbold RF, Bashiardes E, Marcou Y, Michael T, Daniel M, Kakouri E, Papadopoulos P, et al: Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population. Breast Cancer Res Treat. 121:147–156. 2010. View Article : Google Scholar
12	Samusik N, Krukovskaya L, Meln I, Shilov E and Kozlov AP: PBOV1 is a human de novo gene with tumor-specific expression that is associated with a positive clinical outcome of cancer. PLoS One. 8:e561622013. View Article : Google Scholar : PubMed/NCBI
13	Li J, Zhang N, Song LB, Liao WT, Jiang LL, Gong LY, Wu J, Yuan J, Zhang HZ, Zeng MS, et al: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res. 14:3319–3326. 2008. View Article : Google Scholar : PubMed/NCBI
14	Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, DeCaprio JA and Weinberg RA: Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 22:2111–2123. 2002. View Article : Google Scholar : PubMed/NCBI
15	Zhang Z, Li J, Zheng H, Yu C, Chen J, Liu Z, Li M, Zeng M, Zhou F and Song L: Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 18:2685–2693. 2009. View Article : Google Scholar : PubMed/NCBI
16	Song L, Wang L, Li Y, Xiong H, Wu J, Li J and Li M: Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells. J Pathol. 222:227–237. 2010. View Article : Google Scholar : PubMed/NCBI
17	Verkooijen HM, Koot VC, Fioretta G, van der Heiden M, Schipper ME, Rapiti E, Peeters PH, Peterse JL and Bouchardy C: Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: An ecological study comparing two european populations. Breast Cancer Res Treat. 107:389–395. 2008. View Article : Google Scholar
18	Moran-Santa Maria MM, Flanagan J and Brady K: Ovarian hormones and drug abuse. Curr Psychiatry Rep. 16:5112014. View Article : Google Scholar : PubMed/NCBI
19	McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, Gansler T, Thun MJ and Calle EE: Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev. 17:73–79. 2008. View Article : Google Scholar : PubMed/NCBI
20	Ansari J, Hussain SA, Zarkar A, Tanguay JS, Bliss J and Glaholm J: Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep. 20:891–896. 2008.PubMed/NCBI
21	Markman M, Glass T, Smith HO, Hatch KD, Weiss GR, Taylor SA, Goodwin JW and Alberts DS: Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: A Southwest Oncology Group trial. Gynecol Oncol. 88:282–288. 2003. View Article : Google Scholar : PubMed/NCBI
22	Coleman RE: Current and future status of adjuvant therapy for breast cancer. Cancer. 97(Suppl 3): 880–886. 2003. View Article : Google Scholar : PubMed/NCBI
23	Izadi-Mood N, Sarmadi S and Sanii S: Strategies in the histologic diagnosis of low-grade glandular endometrial neoplasm. Curr Opin Obstet Gynecol. 22:43–50. 2010. View Article : Google Scholar
24	Rochefort H, Chalbos D, Cunat S, Lucas A, Platet N and Garcia M: Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. J Steroid Biochem Mol Biol. 76:119–124. 2001. View Article : Google Scholar : PubMed/NCBI
25	Elguero S, Patel B and Liu JH: Misperception of estrogen activity in patients treated with an estrogen receptor antagonist. Am J Obstet Gynecol. 211:e1–e2. 2014. View Article : Google Scholar : PubMed/NCBI
26	Krichevsky AM, King KS, Donahue CP, Khrapko K and Kosik KS: A microRNA array reveals extensive regulation of microRNAs during brain development. RNA. 9:1274–1281. 2003. View Article : Google Scholar : PubMed/NCBI
27	Kawasaki H and Taira K: Hes1 is a target of microRNA-23 during retinoic-acid-induced neuronal differentiation of NT2 cells. Nature. 423:838–842. 2003. View Article : Google Scholar : PubMed/NCBI
28	Li J, Liang S, Yu H, Zhang J, Ma D and Lu X: An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol. 119:543–548. 2010. View Article : Google Scholar : PubMed/NCBI
29	Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN and Wang X: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 114:457–464. 2009. View Article : Google Scholar : PubMed/NCBI
30	Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, et al: miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther. 7:255–264. 2008. View Article : Google Scholar
31	Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, Calin GA and Mukherjee P: miR-15a and miR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 69:9090–9095. 2009. View Article : Google Scholar : PubMed/NCBI